Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Trial Profile

Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Gaucher's disease type I; Gaucher's disease type III
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Orphazyme
  • Most Recent Events

    • 26 Jun 2018 According to an Orphazyme media release,Status changed from planning to recruiting.
    • 21 Jun 2018 According to an Orphazyme media release, first patient has received the first dose. And Results from the Phase II trial are expected in H1 2019.
    • 29 May 2018 According to an Orphazyme media release, company is expected to enroll first patient in Q2 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top